huCD33-BsAb / SERB Pharmaceuticals - LARVOL DELTA

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Y-mAbs Therapeutics | N=36 ➔ 3 | Trial completion date: Sep 2024 ➔ Dec 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Aug 2024 ➔ Dec 2022; Study terminated due to business priorities

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Y-mAbs Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Y-mAbs Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Y-mAbs Therapeutics | Initiation date: Dec 2021 ➔ May 2022

Trial initiation date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics